Biontech announces second quarter 2024 financial results and corporate update

Announced positive data from multiple mrna cancer vaccine clinical trials, including topline results from the ongoing phase 2 evaluating fixvac candidate bnt111 launched updated variant-adapted covid-19 vaccine in the european union (“eu”), received approval in the united kingdom and initiated rolling supplemental biologics licensing application (“sbla”) with the united states food and drug administration (“u.s. fda”) reiterates guidance for total revenues in the range of €2.5-3.1 billion reports second quarter 2024 revenues of €128.7 million, net loss of €807.8 million and loss per share of €3.36 ($3.621) invested €525.6 million or approximately 90% of the company's total r&d spend in q2 in non-covid-19 related activities, mainly oncology and mrna; investments are in line with the reiterated full-year r&d expense guidance ended the second quarter of 2024 with €18.5 billion in cash, cash equivalents and security investments conference call and webcast scheduled for august 5, 2024, at 8:00 a.m. edt (2:00 p.m.
BNTX Ratings Summary
BNTX Quant Ranking